EP4429652A1 — Carbachol formulations to enhance anti-presbyopia effects
Assigned to Visus Therapeutics Inc · Expires 2024-09-18 · 2y expired
What this patent protects
The present disclosure is directed to ophthalmic formulations comprising carbachol, processes for preparing ophthalmic formulations comprising carbachol, viscosity agents, tonicity agents, buffers, and a pH of between 7 to 7.6, and methods of treating presbyopia and other ophthal…
USPTO Abstract
The present disclosure is directed to ophthalmic formulations comprising carbachol, processes for preparing ophthalmic formulations comprising carbachol, viscosity agents, tonicity agents, buffers, and a pH of between 7 to 7.6, and methods of treating presbyopia and other ophthalmic conditions such as hyperopia by administering ophthalmic formulations comprising carbachol to a subject in need thereof.
Drugs covered by this patent
- Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.